Sheffield Clinical Trials Research Unit (CTRU), Sheffield Centre for Health and Related Research, The University of Sheffield, Sheffield, UK
Sheffield Clinical Trials Research Unit (CTRU), Sheffield Centre for Health and Related Research, The University of Sheffield, Sheffield, UK.
BMJ Open. 2024 Mar 19;14(3):e075547. doi: 10.1136/bmjopen-2023-075547.
OBJECTIVES: To explore the importance of, and barriers to achieving, diversity in early-phase clinical trials. DESIGN: Qualitative interviews analysed using thematic analysis. SETTING AND PARTICIPANTS: Five professionals (clinical researchers and methodologists) and three patient and public representatives (those with experience of early-phase clinical trials and/or those from ethnic minority backgrounds) were interviewed between June and August 2022. Participants were identified via their institutional web page, existing contacts or social media (eg, X, formerly known as Twitter). RESULTS: Professionals viewed that diversity is not currently considered in all early-phase clinical trials but felt that it should always be taken into account. Such trials are primarily undertaken at a small number of centres, thus limiting the populations they can access. Referrals from clinicians based in the community may increase diversity; however, those referred are often not from underserved groups. Referrals may be hindered by the extra resources required to approach and recruit underserved groups and participants often having to undertake 'self-driven' referrals. Patient and public representatives stated that diversity is important in research staff and that potential participants should be informed of the need for diversity. Those from underserved groups may require clarification regarding the potential harms of a treatment, even if these are unknown. Education may improve awareness and perception of early-phase clinical trials. We provide 14 recommendations to improve diversity in early-phase clinical trials. CONCLUSIONS: Diversity should be considered in all early-phase trials. Consideration is required regarding the extent of diversity and how it is addressed. The increased resources needed to recruit those from underserved groups may warrant funders to increase the funds to support the recruitment of such participants. The potential harms and societal benefits of the research should be presented to potential participants in a balanced but accurate way to increase transparency.
目的:探讨在早期临床试验中实现多样性的重要性和障碍。
设计:使用主题分析对定性访谈进行分析。
设置和参与者:2022 年 6 月至 8 月期间,对 5 名专业人员(临床研究人员和方法学家)和 3 名患者和公众代表(有早期临床试验经验和/或来自少数民族背景的人员)进行了访谈。参与者是通过他们的机构网页、现有联系人或社交媒体(例如,X,前身为 Twitter)确定的。
结果:专业人员认为多样性目前并未在所有早期临床试验中考虑,但认为应该始终考虑到多样性。这些试验主要在少数几个中心进行,因此限制了他们可以接触到的人群。来自社区的临床医生的转介可能会增加多样性;然而,转介的人往往不是来自服务不足的群体。转介可能会受到向服务不足的群体提出并招募的额外资源的阻碍,而参与者通常不得不进行“自我驱动”的转介。患者和公众代表表示,研究人员的多样性很重要,应该告知潜在参与者多样性的必要性。来自服务不足群体的人可能需要澄清治疗的潜在危害,即使这些危害未知。教育可以提高对早期临床试验的认识和看法。我们提供了 14 条建议,以提高早期临床试验的多样性。
结论:多样性应在所有早期试验中考虑。需要考虑多样性的程度以及如何解决多样性问题。招募服务不足群体所需的额外资源可能需要资助者增加资金,以支持招募这些参与者。应以平衡但准确的方式向潜在参与者介绍研究的潜在危害和社会效益,以提高透明度。
Early Hum Dev. 2020-11
Health Technol Assess. 2004-10
Cochrane Database Syst Rev. 2022-2-1
J Clin Pharmacol. 2022-12
J Racial Ethn Health Disparities. 2023-6
J Clin Transl Sci. 2021-7-14
Cancer. 2021-12-1
Lancet Public Health. 2021-7